Targeted Delivery of TGF-β MRNA to Lung Parenchyma Using One-component Ionizable Amphiphilic Janus Dendrimers

Overview

Journal Res Sq

Date 2024 Jul 23

PMID 39041040

Authors

Elena Atochina-Vasserman

Jaclynn Meshanni

Emily Stevenson

Dapeng Zhang

Rachel Sun

Nathan Ona

Erin Reagan

Elena Abramova

Chang-Jiang Guo

Melissa Wilkinson

Ishana Baboo

Yuzi Yang

Liuyan Pan

Devendra Maurya

Virgil Percec

Yongsheng Li

Andrew Gow

Drew Weissman

Affiliations

Soon will be listed here.

Abstract

Current clinical strategies for the delivery of pulmonary therapeutics to the lung are primarily targeted to the upper portions of the airways. However, targeted delivery to the lower regions of the lung is necessary for the treatment of parenchymal lung injury and disease. Here, we have developed an mRNA therapeutic for the lower lung using one-component Ionizable Amphiphilic Janus Dendrimers (IAJDs) as a delivery vehicle. We deliver an anti-inflammatory cytokine mRNA, transforming growth factor-beta (TGF-β), to produce transient protein expression in the lower regions of the lung. This study highlights IAJD's potential for precise, effective, and safe delivery of TGF-β mRNA to the lung. This delivery system offers a promising approach for targeting therapeutics to the specific tissues, a strategy necessary to fill the current clinical gap in treating parenchymal lung injury and disease.

References

Drzewicka K, Zaslona Z . Metabolism-driven glycosylation represents therapeutic opportunities in interstitial lung diseases. Front Immunol. 2024; 15:1328781. PMC: 10973144. DOI: 10.3389/fimmu.2024.1328781. View

Stevenson E, Wilkinson M, Abramova E, Guo C, Gow A . Intratracheal Administration of Acyl Coenzyme A Acyltransferase-1 Inhibitor K-604 Reduces Pulmonary Inflammation Following Bleomycin-Induced Lung Injury. J Pharmacol Exp Ther. 2022; 382(3):356-365. PMC: 9426763. DOI: 10.1124/jpet.122.001284. View

Schrier D, Kunkel R, Phan S . The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis. 1983; 127(1):63-6. DOI: 10.1164/arrd.1983.127.1.63. View

Chung S, Overstreet J, Li Y, Wang Y, Niu A, Wang S . TGF-β promotes fibrosis after severe acute kidney injury by enhancing renal macrophage infiltration. JCI Insight. 2018; 3(21). PMC: 6238749. DOI: 10.1172/jci.insight.123563. View

Zhang D, Atochina-Vasserman E, Maurya D, Huang N, Xiao Q, Ona N . One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA. J Am Chem Soc. 2021; 143(31):12315-12327. DOI: 10.1021/jacs.1c05813. View

Golden T, Murray A, Venosa A, Gow A . Comprehensive dataset to assess morphological changes subsequent to bleomycin exposure. Data Brief. 2021; 37:107270. PMC: 8365314. DOI: 10.1016/j.dib.2021.107270. View

OCallaghan C . Targeting drug delivery to the lungs by inhalation. Mediators Inflamm. 1994; 3(7):S31-3. PMC: 2365599. DOI: 10.1155/S0962935194000724. View

Zhang D, Atochina-Vasserman E, Maurya D, Liu M, Xiao Q, Lu J . Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers. J Am Chem Soc. 2021; 143(43):17975-17982. DOI: 10.1021/jacs.1c09585. View

Noelle R, Nowak E . Cellular sources and immune functions of interleukin-9. Nat Rev Immunol. 2010; 10(10):683-7. PMC: 3828627. DOI: 10.1038/nri2848. View

10.

Gowda S, Desai P, Hull V, Math A, Vernekar S, Kulkarni S . A review on laboratory liver function tests. Pan Afr Med J. 2011; 3:17. PMC: 2984286. View

11.

Manali E, Moschos C, Triantafillidou C, Kotanidou A, Psallidas I, Karabela S . Static and dynamic mechanics of the murine lung after intratracheal bleomycin. BMC Pulm Med. 2011; 11:33. PMC: 3128859. DOI: 10.1186/1471-2466-11-33. View

12.

Martinez D, Schafer A, Leist S, De la Cruz G, West A, Atochina-Vasserman E . Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science. 2021; 373(6558):991-998. PMC: 8899822. DOI: 10.1126/science.abi4506. View

13.

Rele S . COVID-19 vaccine development during pandemic: gap analysis, opportunities, and impact on future emerging infectious disease development strategies. Hum Vaccin Immunother. 2020; 17(4):1122-1127. PMC: 8018474. DOI: 10.1080/21645515.2020.1822136. View

14.

Izbicki G, Segel M, Christensen T, Conner M, Breuer R . Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002; 83(3):111-9. PMC: 2517673. DOI: 10.1046/j.1365-2613.2002.00220.x. View

15.

Lyons R, Keski-Oja J, Moses H . Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol. 1988; 106(5):1659-65. PMC: 2115066. DOI: 10.1083/jcb.106.5.1659. View

16.

Ogger P, Byrne A . Macrophage metabolic reprogramming during chronic lung disease. Mucosal Immunol. 2020; 14(2):282-295. PMC: 7658438. DOI: 10.1038/s41385-020-00356-5. View

17.

Gur I, Or R, Segel M, Shriki M, Izbicki G, Breuer R . Lymphokines in bleomycin-induced lung injury in bleomycin-sensitive C57BL/6 and -resistant BALB/c mice. Exp Lung Res. 2000; 26(7):521-34. DOI: 10.1080/019021400750048072. View

18.

Wilkinson M, Abramova E, Guo C, Gow J, Murray A, Koudelka A . Fatty acid nitroalkenes inhibit the inflammatory response to bleomycin-mediated lung injury. Toxicol Appl Pharmacol. 2020; 407:115236. PMC: 7662837. DOI: 10.1016/j.taap.2020.115236. View

19.

Johnson E, Matthay M . Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv. 2010; 23(4):243-52. PMC: 3133560. DOI: 10.1089/jamp.2009.0775. View

20.

Visani G, Manfroi S . G-CSF in the biology and treatment of acute myeloid leukemias. Leuk Lymphoma. 1995; 18(5-6):423-8. DOI: 10.3109/10428199509059640. View